LUPUS CLINICAL TRIALS

CURRENTLY ENROLLING:

Name of trial:  A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of BIIB023 in subjects with lupus nephritis

Disease:  Lupus Nephritis

PI:  Dr. Ramon Bonegio

Study contact:  Britte Beaudette-Zlatanova  britte@bu.edu  617-638-5965

                                  Eric Stratton  eas@bu.edu  617-414-2507

Name of trial: Belimumab-A Phase 3, randomized, double-blind, placebo-controlled, 52 week study to evaluate the efficacy and safety of Belimumab administered subcutaneously

Disease: SLE (lupus)

PI: Dr. Robert Lafyatis

Study contact: Britte Zlatanova britte@bu.edu 617-638-5965

Eric Stratton eas@bu.edu 617-414-2507

Name of trial: Epratuzumab-A Phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab

Disease: SLE (lupus)

PI: Dr. Robert Lafyatis

Study contact: Britte Zlatanova britte@bu.edu617-638-5965

Eric Stratton eas@bu.edu617-414-2507 

 

Major inclusion criteria for both studies:

1.  Clinical diagnosis of SLE according to the ACR criteria

2.  Active SLE disease (FLARE)

3.  Positive autoantibody or anti-dsDNA test results at screening